Costilla-Gómez O, Aguilar-Herrera BE, Montero-González P, Cárdenas-Tirado HM

Language: Spanish
References: 23
Page: 143-147
PDF size: 133.65 Kb.

ABSTRACT

Background: Clinical manifestations of Turner´s syndrome are variable, the more constant is short stature that improves with treatment with biosynthetic growth hormone (hGH). Our population is predisposed to the development of insulin resistance, so it is important to evaluate the effects of hGH treatment on insulin resistance in patients with Turner’s syndrome. Material and methods: We evaluated parameters of insulin sensitivity, anthropometric measurements, the effects of estrogen therapy and age in 38 girls with Turner’s syndrome cared for at the General Hospital National Medical Center «La Raza», half of them being treated with hGH. Results: Both groups consisted of 19 patients, similar in age, BMI and estrogen therapy. The patients treated with hGH showed higher values of insulin and HOMA IR and a higher incidence of insulin resistance than the group without treatment (21.05% vs 5.26%), but without significant difference (p › 0.05). Conclusions: In our Mexican group with Turner’s syndrome, despite ethnic characteristics, the frequency of insulin resistance with or without hGH therapy was similar to other reports.

REFERENCES

1. Frías JL, Davenport ML. Committee on genetics and section of endocrinology. Health supervision for children with Turner syndrome. Pediatrics 2003; 111: 692-702.

2. Stochholm K, Juul S, Juel K et al. Prevalence incidence, diagnostic delay, and mortality in Turner syndrome. J Clin Endocrinol Metab 2006; 91: 3897-3902.

3. Alves ST, Gallichio CT, Guimarães MM. Insulin resistance and body composition in Turner syndrome: Effect of sequential change in the route of estrogen administration. Gynecol Endocrinol 2006; 22: 590-594.

4. Ranke MB, Saenger P. Turner´s syndrome. Lancet 2001; 358: 309-314.

5. Gravholt CH, Juul S, Naeraa RW et al. Prenatal and postnatal prevalence of Turner’s syndrome: a registry study. Br Med J 1996; 312: 16-21.

6. Caprio S, Boulware S, Diamond M et al. Insulin resistance: An early metabolic defect of Turner´s syndrome. J Clin Endocrinol Metab 1991; 72: 832-836.

7. Pareren YK, De Muinck S, Stijnen T et al. Effect of discontinuation of long-term growth hormone treatment on carbohydrate metabolism and risk factors for cardiovascular disease in girls with Turner syndrome. J Clin Endocrinol Metab 2002; 87: 5442–5448.

8. Lyon AL, Preece MA, Grant DB. Growth curve for girls with Turner syndrome. Arch Dis Child 1985; 60: 932-935.

9. Cavallo L, Gurrado R. Endogenous growth hormone secretion does not correlate with growth in patients with Turner’s syndrome. Italian Study Group for Turner Syndrome. J Pediatr Endocrinol Metab 1999; 12: 623-627.

10. Davenport ML, Crowe BJ, Travers SH. Growth hormone treatment of early growth failure in toddlers with Turner syndrome: A randomized, controlled, multicenter trial. J Clin Endocrinol Metab 2007; 92: 3406-3416.

11. Sas TC, de Muinck S, Stijnen T et al. Normalization of height in girls with Turner syndrome after long-term growth hormone treatment: results of a randomized dose-response trial. J Clin Endocrinol Metab 1999; 84: 4607-4612.

12. Mazzanti L, Bergamaschi R, Castiglioni L et al. Turner syndrome, insulin sensitivity and growth hormone treatment. Horm Res 2005;64:51-57.

13. Radetti G, Pasquino B, Gottardi E. Insulin sensitivity in Turner’s syndrome: influence of GH treatment. Europ J Endocrinol 2004; 151: 351-354.

14. Hanson RL, Pratley RE, Bogardus C et al. Evaluation of simple indices of insulin sensitivity and insulin secretion for use in epidemiologic studies. Am J Epidemiol 2000; 151: 190-198.

15. Lee LM, Okumura MJ, Davis MM et al. Prevalence and determinants of insulin resistance among US adolescents. Diabetes Care 2006; 29: 2427-2431.

16. Gravholt CH, Weis NR, Brixen K, Kastrup KW, Mosekilde L, Lunde JJO, Sandahl CJ. Short-term growth hormone treatment in girls with turner syndrome decreases fat mass and insulin sensitivity: A randomized, double-blind, placebo-controlled, crossover study. Pediatrics 2002; 110: 889-896.

17. Sas TCJ, Muink KS, Stijnen T, Aanstoot HJ, Drop S. Carbohydrate metabolism during long-term growth hormone (GH) treatment and after discontinuation of GH treatment in girls with Turner syndrome participating in a randomized dose- response study. J Clin Endocrinol Metab 2000; 85: 769-775.

18. Elsheikh M, Dunger DB, Conway GS et al. Turner´s syndrome in adulthood. Endocr Rev 2002; 23: 120-140.

19. Bakalov VK, Cooley MM, Quon MJ et al. Impaired insulin secretion in Turner metabolic syndrome. J Clin Endocrinol Metab 2004; 89: 3516-3520.

20. Pareren YK, De Muinck S, Stijnen T et al. Effect of discontinuation of long-term growth hormone treatment on carbohydrate metabolism and risk factors for cardiovascular disease in girls with Turner syndrome. J Clin Endocrinol Metab 2002; 87: 5442–5448.

21. Kumon Y, Hisatake K, Suehiro T, Sumiyoshi R, Hashimoto K. Insulin resistance in a patient with diabetes mellitus associated with Turner´s syndrome. Inter Med 1994; 33: 560-563.

22. Pasquino A et al. Spontaneous pubertal development in Turner´s syndrome. J Clin Endocrinol Metab 1997; 6: 1810-1813.

23. Massa G et al. Late or delayed induced or spontaneous puberty in girls with Turner syndrome treated with growth hormone does not affect final height. J Clin Endocrinol Metab 2003; 88: 4168-4174.